Therapeutic Drug Monitoring Market Size

Global Therapeutic Drug Monitoring Market size was valued at USD 2.19 Billion in 2023 and is poised to grow from USD 2.37 Billion in 2024 to USD 4.53 Billion by 2032, growing at a CAGR of 8.4% in the forecast period (2025-2032).

Global Therapeutic Drug Monitoring (TDM) Market is slightly picking up pace due to the rising use of personalized medicine and the requirement for improving the dosage of drugs in managing chronic diseases. A primary contributor is promoting market growth is the rising incidence of chronic diseases like epilepsy, autoimmune diseases, and cardiovascular disorders, which demand continuous monitoring of narrow therapeutic index drugs.

The trend towards predictive and precision medicine revolutionizing the TDM environment. The future is likely to center around real-time tracking through point-of-care and digital technologies fused with AI for quicker and more personalized interventions. This is underpinned by R&D collaborations like Roche's recent venture into digital diagnostics and AI-enabled monitoring solutions.

Also, there exists a big potential in the growing demand for access to TDM instruments in developing markets, where the incidence of chronic conditions is high and monitoring infrastructure is poor. Nevertheless, there is still room in the market that is being plagued by challenges including the high cost of testing, varied reimbursement practices, and differences in clinical practice from geography to geography, which could hinder greater penetration.

How are AI-Driven Platforms Transforming the Field of Therapeutic Drug Monitoring?

Artificial intelligence (AI) can revolutionize the therapeutic drug monitoring market with platforms powered by Artificial Intelligence that can interpret patient-specific pharmacokinetic information in real time. For instance, InsightRx, a US company providing clinical software, has created a cloud-based AI solution that is integrated with hospital EMRs to facilitate dose individualization of antimicrobial therapy. Such systems are designed to model drug concentration levels and take into account genetic, demographic, and clinical factors to forecast optimal doses of drugs. The implementation of AI technology assists in minimizing hospitalization time considerably improves therapeutic effects, and reduces adverse drug reactions, thereby improving patient safety and decreasing healthcare expenditure. With AI systems becoming increasingly user-friendly and affordable, their application in mainstream TDM is likely to increase exponentially.

• In May 2023, Google Cloud launched two new AI-driven life sciences solutions to drive drug discovery and precision medicine for biotech firms, pharmaceutical companies, and public sector agencies. The Target and Lead Identification Suite assists scientists in identifying the role of amino acids better and forecasting protein structure; and the Multiomics Suite speeds up the discovery and interpretation of genomic information and assists companies in developing precision treatments.